New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 24, 2013
07:33 EDTTSROTESARO weakness a buying opportunity, says RW Baird
Baird would use the weakness in TESARO shares as a buying opportunity following its secondary endpoint miss in two of its three Rolapitant drug trials. The firm believes the base case for Rolapitant remains intact along with the company's maturing pipeline and additional 2014 catalysts thus they continue to recommend purchases of the shares. Shares are Outperform rated with a $57 price target.
News For TSRO From The Last 14 Days
Check below for free stories on TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for TSRO

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use